Intuitive Surgical (ISRG) has released its Q2 2026 numbers, with revenue of US$2.9 billion and basic EPS of US$2.31, set against trailing 12 month revenue of US$11.0 billion and EPS of US$8.84. Over recent quarters, the company has seen revenue move from US$2.44 billion in Q2 2025 to US$2.89 billion in Q2 2026, while quarterly EPS shifted from US$1.84 to US$2.31, with trailing earnings up 20.4% over the past year and 16.7% per year over the past five years. With a net profit margin of 28.4% and only a slight year over year margin dip, this earnings print puts profitability quality at the center of how investors assess the latest results.
See our full analysis for Intuitive Surgical.With the headline figures on the table, the next step is to set these results against the widely followed market and community narratives to see which views are reinforced and which are being challenged by the numbers.
See what the community is saying about Intuitive Surgical
Earnings Growth Outpaces Revenue Trend
- Over the last year, Intuitive Surgical generated trailing revenue of US$11.0b, growing about 10.9% per year, while trailing EPS reached US$8.84 after rising 20.4% over the same period.
- Consensus narrative highlights strong procedure growth and expanding use across more surgeries, and the recent 20.4% earnings growth versus 10.9% revenue growth shows profit per dollar of sales improving faster than sales themselves. This fits that story but also raises the bar for keeping this earnings pace as growth expectations for the wider US market are higher.
- Forecasts call for earnings growth of about 12.1% per year and revenue of about 10.9% per year, so the latest 20.4% earnings growth sits well above what is currently expected.
- That gap between trailing and forecast growth suggests recent strength is already ahead of the trend analysts are using, leaving less room for upside surprise if earnings simply settle back toward those forecast levels.
Margins Hold Near 28% Despite Pressure
- Net profit margin for Intuitive Surgical is 28.4% on a trailing basis, just below last year's 28.5%, with trailing net income of about US$3.1b on US$11.0b of revenue.
- Bears focus on cost pressures and pricing headwinds, and the tiny move from a 28.5% to 28.4% margin indicates those concerns have not yet shown up as a sharp squeeze, even though revenue growth of 10.9% is slower than the 12.6% rate cited for the broader US market.
- Quarterly net income moved from US$658.4m in Q2 2025 to US$818.1m in Q2 2026 on revenue rising from US$2.44b to US$2.89b, which points to margin stability over several quarters rather than visible erosion.
- This steadiness does not remove the risk of future margin pressure from tariffs or hospital budget limits that bears outline, but current figures show profitability holding up so far against those concerns.
Premium P/E Versus DCF Fair Value Gap
- At a share price of US$345.42, Intuitive Surgical trades on a P/E of 39x, above the US Medical Equipment industry average of 27.2x and peer average of 27.4x, while a DCF fair value of US$435.01 sits above the current price.
- Bulls point to strong earnings growth and recurring revenue to justify that 39x P/E, and the roughly US$89 gap between the current price and the US$435.01 DCF fair value gives them a concrete valuation anchor. However, the slower forecast earnings growth of about 12.1% per year versus the cited 17.8% for the broader US market means the company carries a higher multiple despite slower expected growth than that benchmark.
- Trailing EPS of US$8.84 and a 5 year annual earnings growth rate of 16.7% back the idea of high quality past earnings, which can support paying more than the sector averages if investors are confident that quality persists.
- At the same time, the higher P/E multiple compared with industry and peers leaves the stock more exposed if future earnings growth tracks closer to the forecast 12.1% rather than the stronger 20.4% seen in the last year.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Intuitive Surgical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Given the mix of optimism and caution around Intuitive Surgical, it makes sense to review the details yourself and decide how convincing this earnings story feels. To see exactly what investors are highlighting on the upside, take a closer look at the 3 key rewards.
See What Else Is Out There
For Intuitive Surgical, the key concern is that its premium 39x P/E sits above industry peers, while forecast earnings growth trails the broader US market.
If you are questioning whether that kind of premium still feels comfortable, compare it with companies screened for stronger value using the 47 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com